SAN903, for IPF, Significantly Lessens Fibrosis in Animal Study

SAN903, for IPF, Significantly Lessens Fibrosis in Animal Study

292711

SAN903, for IPF, Significantly Lessens Fibrosis in Animal Study

SAN903, a candidate therapy for idiopathic pulmonary fibrosis (IPF), led to a significant reduction in markers of inflammation and fibrosis (scarring) in a mouse model of induced pulmonary fibrosis (PF), its developer, Saniona, reported. The treatment’s ability to lessen tissue scarring also outperformed that of Esbriet (pirfenidone), an approved antifibrotic therapy marketed by Genentech, in these animals. Dipak Vasantrao Amrutkar, a senior scientist at Saniona, will present these preclinical findings in the poster, “Comparison of The Novel…

You must be logged in to read/download the full post.